Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD0022 |
| Synonyms | |
| Therapy Description |
AZD0022 is a selective inhibitor of KRAS G12D, which potentially inhibits growth of KRAS G12D-overexpressing tumor cells (Cancer Res (2025) 85 (8_Supplement_1): 841, NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD0022 | AZD-0022|AZD 0022 | KRAS G12D Inhibitor 25 | AZD0022 is a selective inhibitor of KRAS G12D, which potentially inhibits growth of KRAS G12D-overexpressing tumor cells (Cancer Res (2025) 85 (8_Supplement_1): 841, NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06599502 | Phase Ib/II | AZD0022 + Cetuximab AZD0022 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) | Active, not recruiting | USA | AUS | 2 |